Naptumomab estafenatox
Naptumomab estafenatox (pronunciation: nap-tu-mo-mab es-ta-fe-na-tox) is a biopharmaceutical drug that was under development for the treatment of various types of cancer. It is a fusion protein that combines parts of a monoclonal antibody specific for the cancer cell surface protein EpCAM with a bacterial toxin.
Etymology
The name "Naptumomab estafenatox" is derived from the components of the drug. "Naptumomab" refers to the monoclonal antibody component, while "estafenatox" refers to the toxin component. The prefix "nap" is derived from the Latin word "nappa", meaning "napkin" or "cloth", which is a metaphorical reference to the drug's ability to "wipe out" cancer cells. The suffix "mab" is a common ending for monoclonal antibodies.
Mechanism of Action
Naptumomab estafenatox works by binding to the EpCAM protein on the surface of cancer cells. Once bound, the toxin component of the drug is internalized by the cell, where it disrupts protein synthesis and leads to cell death.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of Naptumomab estafenatox in various types of cancer, including renal cell carcinoma, non-small cell lung cancer, and ovarian cancer. However, the drug has not yet been approved for use by any regulatory authority.
Related Terms
- Biopharmaceutical
- Monoclonal antibody
- EpCAM
- Toxin
- Clinical trial
- Renal cell carcinoma
- Non-small cell lung cancer
- Ovarian cancer
External links
- Medical encyclopedia article on Naptumomab estafenatox
- Wikipedia's article - Naptumomab estafenatox
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski